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Abstract 
Negative symptoms can be grouped into the two dimensions of diminished expression 
and apathy, which have been shown to be dissociable regarding external validators, such as 
functional outcome.  Here, we investigated whether these two dimensions differentially relate 
to neurocognitive impairment in schizophrenia. 47 patients with schizophrenia or 
schizoaffective disorder and 33 healthy control participants were subjected to a 
neurocognitive test battery assessing multiple cognitive domains (processing speed, working 
memory, verbal fluency, verbal learning and memory, mental planning), which are integrated 
into a composite cognition score. Negative symptoms in patients were assessed using the 
Brief Negative Symptom Scale. We found that diminished expression significantly related to 
neurocognitive impairment, while severity of apathy symptoms was not directly associated 
with neurocognition. Other assessed clinical variables include chlorpromazine equivalents, 
positive symptoms, and depressive symptoms and did not influence the results. Our results are 
in line with a cognitive resource limitation model of diminished expression in schizophrenia 
and indicate that cognitive remediation therapy might be helpful to ameliorate expressive 
deficits.  
Keywords: Schizophrenia, Neuropsychology, Amotivation, Flat affect 
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1. Introduction 
Schizophrenia is a debilitating disorder characterized by positive symptoms (i.e., 
delusions and hallucinations), negative symptoms (i.e., blunted affect, alogia, anhedonia, 
avolition, and asociality) and neurocognitive deficits. While positive symptoms can often be 
successfully treated with antipsychotic medication, negative symptoms and neurocognitive 
deficits seem to be more resistant to current treatments (Arango et al., 2004; Keefe et al., 
2007). Moreover, neurocognitive deficits and negative symptoms have been linked to poor 
functional outcome (G. Fervaha et al., 2014; Milev et al., 2005), emphasizing the need for 
more effective treatment options.  
Neurocognitive deficits are a reliable finding in patients with schizophrenia when 
compared to healthy controls (Fioravanti et al., 2005; Heinrichs and Zakzanis, 1998).  The 
severity of negative symptoms has been reported to correlate with neurocognitive impairment 
cross-sectionally with weak to moderate effect sizes (Addington et al., 1991; Strauss et al., 
2012b). However, there is still a debate about the nature of their relationship (Harvey et al., 
2006). 
There is now consensus in the field that negative symptoms can be grouped into two 
separable dimensions (Foussias and Remington, 2010; Messinger et al., 2011). The first 
dimension, diminished expression, comprises symptoms of blunted affect and alogia. The 
second dimension groups deficits in motivation and pleasure, which manifest themselves as 
symptoms of anhedonia, avolition, and asociality. We refer to this dimension as apathy. 
Diminished expression and apathy have been shown to differentially relate to functional 
outcome (Strauss et al., 2013), decision-making (Hartmann et al., 2015), or neural reward 
processing (Hager et al., 2015; Kirschner et al., 2015), potentially indicating differences in 
underlying mechanisms. In line with this, studies have investigated the cognitive correlates of 
diminished expression and apathy separately. Cohen and colleagues proposed a cognitive 
resource limitation model of diminished expression (Cohen et al., 2012), according to which 
diminished expression is caused by insufficient cognitive resources that are needed for the 
complex initiation and adaptation of gestures and facial and vocal expression. There is 
evidence for this hypothesis in a sample of participants with schizotypal personality (Cohen et 
al., 2012) and schizophrenia (Chang et al., 2014a; Cohen et al., 2013a). However, an early 
study by Blanchard and colleagues found no consistent relation of neurocognitive 
performance with expressive deficits (Blanchard et al., 1994). Moreover, several studies have 
reported that motivational deficits in schizophrenia were linked to poorer performance on 
neurocognitive measures (G. Fervaha et al., 2014; Gard et al., 2009; Nakagami et al., 2008; 
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Roth et al., 2004; Schmand et al., 1994). Recently, studies have investigated correlates of 
neurocognitive deficits with clinical ratings scales that allow the assessment of both negative 
symptom dimensions. Ventura et al. (2014) used the Scale for Assessment of Negative 
Symptoms (SANS; Andreasen, 1982) and reported that both dimensions correlated with 
neurocognitive deficits. Kring et al. (2013) and Gur et al. (2015) reported no significant 
correlations using the Clinical Assessment Interview for Negative Symptoms (CAINS; Kring 
et al., 2013). In a large-scale multicenter study by Galderisi et al. (2014) apathy correlated 
weakly and diminished expression moderately with neurocognitive deficits using the Brief 
Negative Symptom Scale (BNSS; Kirkpatrick et al., 2011). In sum, although it is well 
established that negative symptoms correlate with neurocognitive deficits with weak to 
moderate effect sizes, findings regarding specific relations with negative symptom dimensions 
are inconsistent. Given that the correlation between diminished expression and apathy is 
moderately high (Strauss et al., 2012a), it is thus unclear whether they independently relate to 
neurocognitive deficits or if one dimension is driving the potential association. 
In the current cross-sectional study, we aimed to extend the literature on the 
relationship between negative symptoms and neurocognition in schizophrenia. More 
specifically, we aimed to independently assess the relative contribution of diminished 
expression and apathy (while controlling for variation in the other). Based on the review of 
the literature, we hypothesized to replicate the link between neurocognitive deficits and 
overall negative symptoms. Due to the inconsistency in the literature on the association of 
neurocognitive deficits with the two negative symptom dimensions an exploratory approach 
was pursued in relation to apathy and diminished expression.  
 
2. Methods 
2.1. Participants 
47 patients (SZ) meeting DSM-IV criteria for schizophrenia (n = 41) or schizoaffective 
disorder (n = 6, no mood episode) and 33 healthy control participants (HC) were included in 
the current study. We decided to include patients with schizoaffective disorder, because we 
apply a dimensional approach (Barch et al., 2013; Kaiser et al., 2011). Exclusion of the 
patients with schizoaffective disorder did not change the main results of the paper. Patients 
were either outpatients (n = 20) or post-acute inpatients (n = 27) recruited from units of the 
Psychiatric Hospital of the University of Zurich or affiliated institutions. All patients were 
clinically stable and all but one unmedicated patient received a stable dose of medication. All 
medicated patients received atypical antipsychotics and none of the patients received 
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anticholinergic medication. All inpatients were at the end of their hospitalization and took part 
in a multimodal treatment program and engaged in activities outside of the hospital, allowing 
appropriate assessment of negative symptoms. Diagnoses of schizophrenia or schizoaffective 
disorder were confirmed using the Mini-International Neuropsychiatric Interview (Sheehan et 
al., 1998). Patients were excluded if (a) criteria for any other DSM-IV axis I disorder were 
met, (b) if daily lorazepam dosage exceeded 1 mg, (c) if florid positive symptoms were 
present, that is, any positive subscale item score of the Positive and Negative Syndrome Scale 
(Kay et al., 1987) higher than four, or (d) if extrapyramidal symptoms were present on clinical 
examination. Thus, in line with the NIMH-MATRICS consensus statement on negative 
symptoms (Kirkpatrick et al., 2006), we defined our exclusion criteria to control for principal 
sources of secondary negative symptoms (positive symptoms, depression, medication side-
effects). There was no inclusion criterion with respect to negative symptom severity, as we 
aimed to include patients with broad range of symptom severity. HC participants were also 
screened for neuropsychiatric disorders with the Mini-International Neuropsychiatric 
Interview (Sheehan et al., 1998) to ensure the absence of  previous or present neuropsychiatric 
illness. The present study was approved by the local ethics committee (ethics committee of 
the canton of Zurich) and written informed consent was obtained from all participants.  
 
2.2. Clinical Rating Scales  
To assess negative symptoms, we applied the BNSS (Kirkpatrick et al., 2011) in the 
patient sample. The BNSS was translated to German by the senior author and back-translated 
by an attending psychiatrist who was BNSS-naïve and native English speaking. Assessment 
of inter-rater reliability showed an excellent intra-class correlation coefficient (ICC) of .97 for 
the total score and .87 to .97 for the subscales (anhedonia: .88, asociality: ..95, avolition: .87, 
blunted affect: .95; alogia: .97; Bischof et al., submitted). The diminished expression 
dimension included the subscales alogia and blunted affect, while the apathy dimension 
included anhedonia, asociality, and avolition subscales. 
Further psychopathological assessment included the PANSS (Kay et al., 1987), the 
Personal and Social Performance Scale (Schaub and Juckel, 2011), and the Calgary 
Depression Scale for Schizophrenia (CDSS; Addington, Addington, & Schissel, 1990). 
 
2.3. Neuropsychological Assessment 
Participants were subjected to a test battery that assessed performance in 
neurocognitive domains commonly impaired in schizophrenia (processing speed, working 
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memory, verbal fluency, verbal learning and memory, mental planning) (Heinrichs and 
Zakzanis, 1998). The test battery included the the following tests: Digit-Symbol Coding and 
Digit Span of the Wechsler Adult Intelligence Scale Version III (Von Aster et al., 2006), 
Corsi block-tapping test (Kessels et al., 2000), verbal fluency (Delis et al., 2001), Rey 
Auditory Verbal Learning Test (Helmstaedter and Durwen, 1990), and the Tower of London 
(Shallice, 1982). Please note that the applied test battery is not exhaustive in terms of reported 
neurocognitive deficits in schizophrenia, i.e. there were no tests of motor deficits, visual 
learning or social cognition. 
Five neuropsychological domain scores were calculated from indices of the assessed 
tests: processing speed (Digit-Symbol Coding), working memory (mean of Digit Span 
backwards and Corsi block-tapping test backwards), verbal fluency (mean of semantic and 
phonemic fluency), verbal learning and memory (mean of RAVLT total words recalled in all 
trials and RAVLT delayed recall), mental planning (Tower of London). We calculated a 
composite cognition score as the weighted mean of these five neuropsychological domains, 
which were previously z-transformed based on the data of the HC group.  
To control for lack of effort in the neuropsychological assessment, we calculated the 
Reliable Digit Span (RDS; Greiffenstein et al., 1994) as an embedded performance validity 
test. The RDS is calculated as the sum of the longest number of digits correctly repeated in 
the forward and backward condition of the Digit Span test of the Wechsler Adult Intelligence 
Scale Version III (Von Aster et al., 2006). We applied the conservative cut-off criterion of ≤ 6 to avoid false positives.  
 
2.4. Statistical Analyses 
Potential group differences in demographic and cognitive measures were assessed 
using two-sample t or Mann-Whitney U tests for continuous and chi-square tests for 
categorical variables. Degrees of freedom were adjusted if Levene’s test indicated inequality 
of variances. Effect sizes of group differences are reported as Cohen’s d, r or Phi coefficient. 
Bivariate relationships between the two negative symptom dimensions of apathy and 
diminished expression, the five neuropsychological domains, and the composite cognition 
score were assessed using Pearson correlation coefficients. To test whether the correlations 
between the two symptom dimension and neurocognition were significantly different, we 
applied Steiger’s Z-test (Steiger, 1980). Next, we computed partial correlations to 
independently assess the relationship between each of the two dimensions and performance in 
the neurocognitive domains while controlling for the other dimension. Additionally, 
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hierarchical multiple regression was used to evaluate the contribution of diminished 
expression and apathy in predicting composite cognition. In a first model, apathy was entered 
first followed by diminished expression, while the second model was computed vice versa. 
Effect sizes of regression models are reported as Cohen’s f2. 
The current paper reports multiple statistical inferences, which increases the chance of 
false positives. Considering the exploratory nature of the study, we did not adjust the p-values 
for multiple comparisons. All analyses were conducted using SPSS version 22 (IBM Corp.).  
 
3. Results 
3.1. Sample Characteristics 
Demographic and clinical characteristics and cognitive test scores of the SZ and HC 
group are presented in Table 1. SZ participants performed significantly worse in the cognitive 
domains of processing speed, verbal fluency, verbal learning and memory, mental planning, 
and also on the composite cognition score. However, differences in the working memory 
score did not reach significance. 
Three patients failed to pass the performance validity test (RDS; cut-off criterion ≤ 6) 
with a value of 6 (6.4% of total patient sample), while none of the control participants failed 
the criterion. Groups were not significantly different regarding performance validity (Fisher’s 
Exact Test; p = .26). Due to the small number of failures, the issue of disentangling lack of 
effort from motivational negative symptoms, and the fact that exclusion did not change our 
main conclusion (see 3.2.), we decided to include all patients in further analyses.  
 
3.2. Correlational Analyses 
Bivariate Pearson correlations (r) between negative symptoms and cognitive test 
scores are presented in Table 2. Significant correlations with both negative symptom 
dimensions were found with the domains of verbal fluency and verbal learning and memory. 
However, the correlations between symptoms and the domains of processing speed, working 
memory, and mental planning were not significant. Only the dimension diminished expression 
correlated significantly with the composite cognition score, while the correlation with the 
apathy dimension did not reach significance. However, according to a Steiger’s Z-test these 
correlations were not significantly different from each other (Z = 1.00, p = 0.32). 
Although diminished expression and apathy segregate as independent dimensions in 
factor analytic studies, they co-occur in patients with schizophrenia. In the current study, the 
correlation was r = .44 (p = .002). We applied partial correlations to independently assess the 
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dimensions relation with the neurocognitive domains and composite cognition (see Table 2 
coefficients in brackets). None of the cognitive test indices were related to apathy when 
variation in severity of diminished expression was held constant. However, when apathy was 
held constant, diminished expression significantly correlated with verbal learning and 
memory and mental planning and the composite cognition score.   
Other relevant clinical and demographic variables (chlorpromazine [CPZ] equivalents, 
positive symptoms, depressive symptoms, age) were not significantly associated with 
composite cognition (all r’s < .22, all p’s > .14). The partial correlation between diminished 
expression symptoms and composite cognition score (controlling for apathy symptoms) 
remains significant when holding CPZ equivalents, positive symptoms, depressive symptoms, 
and age constant (r = -.41, p = .008).  
 
3.3. Regression Analyses  
Hierarchical multiple regression was used to further investigate the contribution of 
diminished expression and apathy in predicting composite cognition (Table 3). In the first 
model, diminished expression predicted 14% of the variance, with apathy accounting for no 
additional variation in neurocognitive performance (Table 3A). A second model with apathy 
entering the model first, revealed that apathy explained .5% of the neurocognitive deficits, 
while diminished expression accounted for an additional 13.5% of the variance (Table 3B). 
This indicates that the link between negative symptoms and neurocognitive deficits in the 
present patient sample is mainly driven by variation in expressive deficits. 
 
4. Discussion 
Here, we investigated whether the two negative symptom dimensions of diminished 
expression and apathy differentially relate to neurocognitive impairment in schizophrenia. On 
the level of cognitive subdomains, it was found that verbal fluency and verbal learning and 
memory were significantly associated with both negative symptom dimensions, while only 
diminished expression significantly correlated with a composite cognition score. When 
variation in the other dimension was controlled for, verbal fluency, verbal learning and 
memory, and mental planning showed significant correlations with diminished expression. 
However, none of the partial correlations between apathy and neurocognitive domains 
reached significance. Moreover, when the two symptom dimensions are entered into one 
regression model, only diminished expression meaningfully predicts neurocognitive deficits. 
It is important to note that we excluded patients with the principal causes of secondary 
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negative symptoms – current psychosis, depression and extrapyramidal side-effects. 
Furthermore, the results were not driven by clinical variables, such as chlorpromazine 
equivalents, positive symptoms, depressive symptoms or age of the patients. In other words, 
the observed associations are likely to be driven mainly by primary negative symptoms.  
The main finding of the current study, the association of diminished expression with 
decreased overall cognitive performance, is in line with the cognitive resource limitation 
theory proposed by Cohen and colleagues (Cohen et al., 2012). This theory states that if 
cognitive performance is decreased in a psychiatric disorder, such as SZ, fewer resources are 
available for complex expressive action and interaction. Studies supporting the theory by 
Cohen et al. in regard to schizophrenia have used a self-report measure (Cohen et al., 2012), a 
clinician rating scale (Chang et al., 2014b), or a computerized acoustic analysis (Cohen et al., 
2013b) to assess symptoms of diminished expression. Recent studies have assessed 
diminished expression together with apathy in clinical rating scales, reporting mixed results 
regarding their link to neurocognitive deficits (Galderisi et al., 2014; Gur et al., 2015; Kring et 
al., 2013; Ventura et al., 2014). Critically, none of these studies investigated the independent 
relationship of the two negative symptom dimensions with cognitive function. Here, we took 
this into account and found that dominant role of diminished expression in driving the 
negative symptom-cognition link.   
In partial contrast to our data, studies have suggested that motivational deficits (i.e., 
apathy) in schizophrenia are linked to cognitive deficits (Gagan Fervaha et al., 2014; Roth et 
al., 2004), especially to deficits in executive functions (Faerden et al., 2009; 
Konstantakopoulos et al., 2011). In the present study, the correlation between apathy and 
composite cognition failed to reach significance. Moreover, apathy did not correlate 
significantly with tests probing executive functions (working memory and mental planning). 
These discrepancies might be due the moderate sample size of the present study or differences 
in applied instruments to assess symptoms and neuropsychological functioning.  However, 
although our data suggest a stronger link of diminished expression with cognition, it is 
plausible that motivational deficits also impact cognitive performance. Notably, the causal 
chain linking symptoms and cognition might be crucially different. According to the cognitive 
resource limitation model, cognitive deficits cause a reduction in expression, while above 
mentioned studies argue that motivational deficits would cause deficits in cognitive 
performance. Further research is needed to elucidate these potentially complex interactions. 
Ratings on the degree of diminished expression and apathy rely on different sources of 
information. The clinician makes inferences about apathy (i.e., anhedonia, asociality, 
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avolition), which are limited by the patient’s awareness and ability to accurately 
communicate. Diminished expression, on the other hand, is rated according to direct 
observation of the patient’s behavior during the interview. The validation of the German 
version of the BNSS indicated that apathy dimension showed lower inter-rater reliability than 
diminished expression. Thus, we cannot rule out the possibility that this (less noise in the 
measurement of diminished expression) might have contributed to the present results. 
A few limitations of the present study warrant mention. First, considering the expected 
moderate effect sizes in the association of negative symptoms with cognitive deficits and the 
considerable correlation between the two negative symptom dimensions, our findings have to 
be replicated in larger samples allowing the study of additional moderator variables. Well-
powered future studies will also provide more information about whether the two dependent 
correlations of the negative symptom dimensions with neurocognition are significantly 
different. In the current study, the statistical test regarding this question did not reach 
significance. Second, although we used validated cognitive tests to probe the main cognitive 
domains, future studies should use consensus cognitive test batteries (Nuechterlein et al., 
2008) for improved comparability across studies.  
In conclusion, our data are in agreement with the cognitive resource limitations model 
of diminished expression (Cohen et al., 2012). They extend our knowledge about potential 
mechanisms underlying negative symptoms and have implications for their treatment. In 
addition to cognitive behavioral therapy to address apathy in schizophrenia, cognitive 
remediation therapy could be applied to target diminished expression. Until now, cognitive 
remediation has been found in some but not all studies to improve overall negative symptoms 
(Dickinson et al., 2010; Sánchez et al., 2014). Our findings clearly suggest that apathy and 
diminished expression need to be addressed as separate outcomes in order to clarify the effect 
of cognitive remediation on negative symptoms. Treatment development seems to be 
especially important considering that diminished expression might affect the successful 
maintenance of social and romantic interaction, which in turn might establish or worsen 
symptoms of apathy. Further studies are needed to clarify the neurobiological basis of this 
symptom-cognition link, and to evaluate potential specific treatment effects of cognitive 
remediation therapy on diminished expression. Moreover, it would be of interest to 
investigate whether cognitive deficits in other psychiatric conditions (e.g., depression) also 
show a link to diminished expression.  
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Table 1 
Demographic and clinical characteristics and cognitive test scores. 
  
 
Healthy controls 
(n = 33) 
Patient group 
(n = 47) 
Test 
statistic 
p-value 
 
Effect size 
 
Demographics      
 Age (years) 33.01 (9.64) 31.30 (7.71) t = 0.92 .36 d = .21 
 Gender (male/female) 22/11 34/13 χ2 = 0.30 .59 Phi = .06 
 Handedness (r/l) 29/4 43/4 χ2 = 0.28 .60 Phi = -.06 
 Education (years) a 12.53 (3.30) 11.29 (2.74) U = 606.00 .09 r = .19 
Clinical variables      
 CPZ equivalents - 566.29 (428.88) - - - 
 
Duration of illness 
(years) 
- 8.89 (6.69) - - - 
  Apathy (BNSS b)  - 16.15 (8.42) - - - 
 
Diminished expression 
(BNSS b)  
- 9.49 (7.26) - - - 
 PANSS positive c - 7.17 (2.90) - - - 
 PANSS negative c - 14.30 (5.93) - - - 
 PSP scale - 54.87 (11.39) - - - 
 CDSS - 1.91 (2.28) - - - 
Cognitive test scores       
 Processing speed 0 (1) -1.08 (.94) t = 4.92 < .001 d = 1.12 
 Working memory 0 (1) -.35 (1.45) U = 656.50 .24 r = .13 
 Verbal fluency 0 (1) -1.00 (.99) t = 4.39 < .001 d = 1.00 
 
Verbal learning and 
memory 
0 (1) -1.03 (1.26) t = 3.92 < .001 d = .89 
 Mental planning 0 (1) -.44 (.94) U = 572.50 .04 r = .23 
 
Composite cognition 
score 
0 (1) -1.24 (1.28) t = 4.84 < .001 d = 1.10 
Note. Data are presented as means and standard deviations.  BNSS = Brief Negative Symptom Scale; CDSS = Calgary 
Depression Scale for Schizophrenia; CPZ = Chlorpromazine; PANSS = Positive and Negative Syndrome Scale; PSP = 
Personal and Social Performance. a Compulsory education in Switzerland is 9 years. b Apathy: sum of anhedonia, asociality, 
and avolition; diminished expression: sum of blunted affect and alogia. c Positive factor: P1, P3, P5, G9; negative factor: N1, 
N2, N3, N4, N6, G7.  
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Table 2 
Correlation coefficients between the negative symptom dimensions diminished expression 
and apathy and cognitive test scores in the patient group (n = 47).  
 
 
Diminished expression  
(BNSS) 
Apathy  
(BNSS) 
Processing speed -.09 (-.02) -.20 (-.19) 
Working memory -.28 (-.25) -.08 (.06) 
Verbal fluency -.33* (-.21) -.38* (-.27) 
Verbal learning and memory -.42** (-.33*) -.32* (-.17) 
Mental planning -.25 (-.36*) .14 (.28) 
Composite cognition score -.37* (-.31*) -.22 (-.07) 
Note. Values are Pearson correlations and partial correlations in brackets (each symptom dimension controlled 
for the other one). BNSS = Brief Negative Symptoms Scale.  
* p < .05, ** p < 0.01 
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Table 3 
Predictors of the composite cognition score in stepwise hierarchical multiple regression. 
 
A R2 f2 Beta p 
Step 1     
 
Diminished 
Expression 
.14 .16 -.37 .01 
Step 2     
 
Diminished 
Expression 
.14a .16a -.34 .04 
 Apathy  .0b -.07 .65 
      
B R2 f2 Beta p 
Step 1     
 Apathy .05 .05 -.22 .14 
Step 2     
 Apathy .14a .16a -.07 .65 
 
Diminished 
Expression 
 .10b -.34 .04 
Note.  BNSS = Brief Negative Symptoms Scale. aValues relate to the whole model in step 2. bEffect size 
attributable to the addition of second variable to the model.  
 
